Oncolytic virus immunotherapy: future prospects for oncology

The immunology of hepatocellular carcinoma

(2018) Marc Ringelhan et al.   NATURE IMMUNOLOGY

Tissue-resident memory T cells at the center of immunity to solid tumors

(2018) Derk Amsen et al.   NATURE IMMUNOLOGY

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

(2016) Praveen K. Bommareddy et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Coley’s Lessons Remembered

(2016) Maurice Orange et al.   INTEGRATIVE CANCER THERAPIES

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Current status of immunotherapy

(2016) Susumu Suzuki et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances

(2016) J. L. Messerschmidt et al.   ONCOLOGIST

The concept of immune surveillance against tumors: The first theories

(2016) Domenico Ribatti   Oncotarget

Oncolytic Viruses: Therapeutics With an Identity Crisis

(2016) Caroline J. Breitbach et al.   EBioMedicine

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

(2015) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

(2015) Ilkka Liikanen et al.   OncoImmunology

Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression

(2014) A. Sucker et al.   CLINICAL CANCER RESEARCH

Immunotherapy in gastric cancer

(2014) Satoko Matsueda   WORLD JOURNAL OF GASTROENTEROLOGY

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

(2013) C. J. Breitbach et al.   CANCER RESEARCH

The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer

(2013) C. Y. Slaney et al.   CANCER RESEARCH

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

(2013) Dung T. Le et al.   JOURNAL OF IMMUNOTHERAPY

Personalized Oncology in Interventional Radiology

(2013) Nadine Abi-Jaoudeh et al.   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Vascular remodeling in cancer

(2013) R H Farnsworth et al.   ONCOGENE

Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

(2012) Emmanuel S Antonarakis   ASIAN JOURNAL OF ANDROLOGY

Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

(2012) S. Miyamoto et al.   CANCER RESEARCH

Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets

(2012) Janice A. Nagy et al.   CLINICAL & EXPERIMENTAL METASTASIS

Cancer immunoediting by the innate immune system in the absence of adaptive immunity

(2012) Timothy O’Sullivan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Ravi A Madan et al.   LANCET ONCOLOGY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Clinical development directions in oncolytic viral therapy

(2011) R M Eager et al.   CANCER GENE THERAPY

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Viral Vector-Based Therapeutic Cancer Vaccines

(2011) Cecilia Larocca et al.   CANCER JOURNAL

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

(2011) Alan Melcher et al.   MOLECULAR THERAPY

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

(2011) Kelley A Parato et al.   MOLECULAR THERAPY

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Double trouble for tumours: Exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses

(2010) Naomi De Silva et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1

(2010) B Huang et al.   GENE THERAPY

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?

(2009) A. Hamaï et al.   TISSUE ANTIGENS

Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors

(2008) B Yaacov et al.   CANCER GENE THERAPY

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY

Phase I Study of Noninvasive Imaging of Adenovirus-mediated Gene Expression in the Human Prostate

(2008) Kenneth N Barton et al.   MOLECULAR THERAPY

NK cells and cancer immunosurveillance

(2008) I Waldhauer et al.   ONCOGENE